From Importing to Manufacturing: Avalon Pharma and the

Middle East Pharmaceutical Industries Company (Avalon Pharma) announced that it has signed a licensing agreement with One Source Specialty Pharmaceuticals Limited.
Under the agreement, Avalon Pharma has obtained an exclusive license to register and market the drug “tirzepatide” (a generic version of “Mounjaro KwikPen”) in the Kingdom of Saudi Arabia and the Middle East and North Africa region.
The contract runs for 10 years from the date of commercial launch, with the project expected to generate cumulative revenues of at least SAR 800 million during the first five years.
This strategic step aims to strengthen the company’s portfolio in diabetes and metabolic disease treatment, with the possibility of transferring manufacturing technology at a later stage, in line with the objectives of Saudi Vision 2030.

Students from Al Yamamah University discussed the financial and strategic dimensions of this agreement and its impact on the company’s market share and cash flows, as follows:

Building sustainable market share and transferring technology to support pharmaceutical security

Student Zikra Abdulkareem @Zikra Abdulkareem shared her perspective, saying: “I believe this partnership represents a strong opportunity for Avalon Pharma, especially given the significant growth in the diabetes and obesity drug market.
The projected revenues of SAR 800 million over 5 years could boost the company’s growth and profitability, but the more important factor is its ability to build sustainable market share.
The option to transfer manufacturing technology locally is also strategically important, as it supports the company’s expansion, strengthens local pharmaceutical security, and aligns with the objectives of Saudi Vision 2030.”

Pricing and distribution challenges, and reducing production costs through localization

Student Rabiah Almugait @Rabiah Almugait also shared her views, explaining: “The agreement presents a good opportunity for Avalon Pharma to increase its revenues and expand into new markets, particularly amid rising demand for diabetes and obesity drugs.
However, achieving the projected revenues depends on how quickly the drug is registered and launched, and on the company’s ability to compete on price and distribution.
In the long term, transferring manufacturing technology to Saudi Arabia would reduce production costs, strengthen the company’s position, and support the localization of pharmaceutical manufacturing in line with Saudi Vision 2030.”

Accounting distinction between projected revenues and sustainable actual profits

Student Albatool Bedairi @Albatool Bedairi explained: “I believe the agreement represents an important opportunity for Avalon Pharma to boost revenue growth and diversify its pharmaceutical portfolio, particularly since cumulative revenues are expected to reach at least SAR 800 million in the first five years after commercial launch.
From an accounting perspective, however, it is important to distinguish between projected revenues and actual profits, since generating sales does not necessarily mean achieving high profit margins, especially given the costs of supply, marketing, and distribution.
In my view, sustained profitability depends on actual demand, effective cost management, and the company’s ability to maintain its market share throughout the term of the agreement.
Nor can all projected revenues be recognized when the contract is signed; revenues are recognized only when the accounting recognition criteria are met.”

Balancing sales growth with operating cash flows

Student Jana Alshahrani @Jana Alshahrani added: “Avalon Pharma’s agreement reflects a strategic shift toward a high-demand pharmaceutical market, with projected revenues of at least SAR 800 million over five years, averaging SAR 160 million annually, or approximately 29% of the company’s estimated annual revenues.
Despite the scale of the opportunity, sales growth does not guarantee increased profits, particularly given a 68.7% rise in capital expenditure and a 36.1% decline in operating cash flows.
The agreement gives Avalon Pharma a competitive advantage through exclusive rights to market “tirzepatide” across multiple markets, but its success depends on pricing, product availability, and regulatory approvals—not exclusivity alone.
In my view, the greatest value lies in the possibility of transferring manufacturing technology to the Kingdom, which would improve cost efficiency and pharmaceutical security and support Vision 2030.
Therefore, the agreement’s success should not be measured solely by projected revenues, but by its ability to generate sustainable profitability and cash flows.”

Improving financial performance and developing national expertise in pharmaceutical manufacturing

Student Raneem Asiri @Raneem Asiri affirmed: “I believe this partnership is a positive step for Avalon Pharma because it opens up new opportunities in the diabetes and obesity drug market, where demand is growing.
I believe the projected revenues could help the company expand and improve its financial performance over the long term.
The possibility of manufacturing the drug locally is also an important advantage, as it supports Saudi Vision 2030 and creates opportunities to develop national expertise in pharmaceutical manufacturing.”

Sustaining strong profitability and improving operational efficiency through local manufacturing

Student Ryouf Alsewailim @Ryouf Alsewailim noted: “Projected revenues of SAR 800 million ensure strong profitability and financial growth for the company in the coming years.
Entering the diabetes and obesity drug sector with an alternative product also gives the company a strong ability to compete and attract a broad segment of the market.
In addition, transferring technology and manufacturing locally will improve the company’s operational efficiency and directly support pharmaceutical security objectives and Vision 2030.”

The direct impact of the speed of commercial launch on sustaining sales

Student Haifa Almutairi @Haifa Almutairi shared her view, explaining: “In my view, the Avalon Pharma agreement represents a strategic opportunity to boost revenue growth and expand market share, especially amid rising demand for diabetes and obesity drugs.
The option of transferring manufacturing locally could also improve operational efficiency and profit margins in the future.
I believe the agreement’s positive impact will depend primarily on the speed of commercial launch, the ability to compete, and the achievement of sustainable sales.”

Preparing infrastructure and maximizing profit margins through the “Avalon 4” plant

Student Ahmed Al Jadaan @AHMED ALJADAAN explained: “The most important aspect of this agreement is the option to transfer manufacturing technology in the future.
The company is currently making substantial capital investments (up 68.7% to SAR 33.9 million) to build the “Avalon 4” plant.
This means the partnership is not merely about marketing and distribution; it lays the groundwork for manufacturing these modern drugs at the company’s new plant in the future.
This will maximize its profit margins (currently stable at 21.1% as net profit) and support the Kingdom’s pharmaceutical security.”

Prioritizing cash flow management before expanding local manufacturing

Student Yazan Hamoud @Yazan Hamoud added: “I believe the Avalon Pharma agreement is a good growth opportunity, particularly with expected revenues exceeding SAR 800 million over 5 years.
What caught my attention, however, was that operating cash flows fell by 36.1% despite profit growth.
In my opinion, the company should first focus on successfully marketing the drug and generating stable cash flows before expanding into local manufacturing, because higher revenues do not necessarily mean improved liquidity and profitability.”

Linking product expansion to the need for efficient cash flow management

Student Mohammad Alghaihab @Mohammad Alghaihab affirmed: “I believe the Avalon Pharma agreement is a positive step, particularly as the company expects revenues of more than SAR 800 million during the first five years after the product launch. This will open up a new source of income and strengthen its presence in the diabetes and obesity drug market.
What caught my attention, however, was the company’s financial position, especially since operating cash flows fell to SAR 34 million despite profit growth, making liquidity management critically important as the company expands and launches new products.
In my view, the greatest opportunity is not limited to marketing the drug; it also lies in the possibility of transferring manufacturing technology locally, as this could increase the company’s added value and improve its competitiveness over the long term.
Nevertheless, the agreement’s success will remain linked to regulatory approvals, operating costs, and actual profit margins.”

Reducing reliance on imports and strengthening supply chain efficiency

Student Nouf Alojayan @Nouf Alojayan noted: “I believe the agreement represents a strong opportunity for Avalon Pharma to increase its revenues and strengthen its market share, especially given rising demand for diabetes and obesity drugs.
However, sustainable profits depend on its ability to manage costs and compete effectively, and to convert projected revenues into actual profits.
Moreover, transferring manufacturing technology locally in the future could reduce reliance on imports and improve supply chain efficiency, while also supporting pharmaceutical security and achieving the objectives of Vision 2030.”

Price competitiveness and early registration to strengthen regional market share

Student Shahad Alkhamis @Shahad Alkhamis shared her view, explaining: “I believe this partnership represents a major step forward for Avalon Pharma. The target of SAR 800 million in cumulative revenues over five years seems reasonable given the scale of demand for diabetes and obesity drugs.
However, sustained profitability will depend on the company’s ability to manage profit margins in a competitive market where prices are trending downward as more generic alternatives enter.
The most significant competitive opportunity lies in combining an early launch with competitive pricing for a drug equivalent to “Mounjaro.” This could give the company a strong foothold in Saudi Arabia and the region if it secures broad coverage through hospital and retail channels before competition intensifies.
The real value of the deal, however, lies in its technology transfer provision, which would transform Avalon Pharma from a distributor into a local manufacturer of modern medicines, strengthen pharmaceutical security, and align with Vision 2030. It is the strongest guarantee of sustaining the company’s operational value over the long term.”

Turning target returns into profits and sustainable growth for shareholders

Student Thanaa Alshayib @Thanaa Alshayib explained: “I believe the agreement represents a major opportunity for Avalon Pharma, especially given the growing demand for diabetes and obesity drugs.
Targeting SAR 800 million in revenues over 5 years is ambitious, but what matters most is how this figure will translate into company profits and long-term growth.
More important still, in my view, is the option of local manufacturing, as it could give the company a stronger competitive advantage, reduce its reliance on imports, and open up greater opportunities for expansion in the Saudi market and the region.
In short, the agreement’s success will not be measured solely by the volume of revenues, but by Avalon Pharma’s ability to turn this opportunity into sustainable growth and real profits over the long term.”

Moving from distribution to manufacturing to increase operating profit margins

Student Fay Aldossari @Fay Aldossari added: “This is a very strong strategic partnership for Avalon Pharma.
The projected figures (SAR 800 million) reflect strong demand for diabetes and obesity drugs, and the company’s entry into this sector will secure sustainable cash flows.
Most importantly, the technology transfer will transform the company from a mere distributor into a local manufacturer of the latest medicines. This will increase its profit margins and support pharmaceutical security as part of the objectives of Vision 2030.”

Medical awareness and supply reliability in addressing side-effect challenges

Student Faiz Alhaj @Faiz Alhaj affirmed: “The financial impact of this agreement is highly significant: cumulative revenues of at least SAR 800 million in the first 5 years is a substantial figure—around SAR 160 million annually, or close to 30% of the company’s current annual revenues—under a contract worth less than 5% of its revenues.
These are revenues, not profits, but with a stable net profit margin of 21.1%, I expect them to support profit growth in the medium and long term.
As for competition in the GLP-1 drug market, I believe Avalon Pharma’s main advantages will be price, local availability, and speed of registration and distribution, in a market experiencing unprecedented global and regional demand.
One challenge is that “tirzepatide” carries the known side effects associated with this class of drugs, which may affect some patients’ adherence to treatment.
Therefore, Avalon Pharma’s advantage will depend on demonstrating the product’s quality and safety, and on providing medical support and awareness, in addition to competitive pricing and local availability—particularly as other competitors enter after patent expiry.
Regarding technology transfer, I believe the company’s transition from distributor to local manufacturer is a strategic step.
A production base is stronger than distribution alone: it increases margins, reduces reliance on imports, supports pharmaceutical security and Vision 2030, and aligns with the development of the “Avalon 4” plant.”

Strengthening supply chain resilience and building trust among healthcare professionals

Student @عمر الشيخ noted: “In my view, Avalon Pharma’s exclusive partnership to market “tirzepatide” represents a strategic opportunity to achieve sustainable growth, strengthen the company’s competitiveness, and contribute to the localization of pharmaceutical industries in the Kingdom.
Financially, projected cumulative revenues of at least SAR 800 million during the first five years could help diversify the company’s income sources and strengthen its presence in the diabetes and weight management drug market.
However, revenue growth does not necessarily mean high profits; that requires efficient management of supply, marketing, and distribution costs, as well as monitoring profit margins and cash flows.
From a competitive standpoint, exclusive marketing rights could give Avalon Pharma an opportunity to establish a strong position in a rapidly growing market.
Its success, however, will depend on obtaining the necessary regulatory approvals, the expiry of relevant patents, product quality, continuity of supply, and the company’s ability to offer it at a suitable price.
Building trust among healthcare professionals and patients will also be a key factor in its success.
Finally, the option to transfer manufacturing technology could create long-term strategic value.
Local manufacturing can strengthen supply chain resilience, improve control over production and quality, help develop specialized national talent, and support Saudi Vision 2030 objectives for localizing pharmaceutical industries.
However, the decision to transfer technology should be based on a careful assessment of costs and returns, including equipment, technologies, human resources, quality requirements, and regulatory compliance.
In conclusion, I believe this partnership’s success should not be measured by projected revenues alone, but by its ability to generate sustainable profits, ensure reliable supplies of medicines, and strengthen local manufacturing capabilities. The real opportunity lies in turning an exclusive licensing agreement into a sustainable competitive advantage.”

Securing a strong market share amid growth in the weight-loss drug sector

Student Fahad Alruwaished @Fahad Alruwaished shared his view, explaining: “Avalon Pharma’s signing of an exclusive licensing agreement for “tirzepatide” (the generic version of “Mounjaro”) represents a major leap forward in boosting the company’s revenues and sustaining its profitability over the medium and long term. The product is expected to generate cumulative revenues of at least SAR 800 million during the first 5 years after commercial launch.
Against the backdrop of unprecedented global and regional demand for diabetes and obesity drugs, providing this equivalent alternative to “Mounjaro” gives Avalon Pharma an exceptional competitive opportunity to secure a strong market share in the Kingdom and the Middle East and North Africa region, capitalizing on the enormous demand and rapid growth of this vital sector.”

Value-based pricing and product availability as a strategic alternative to stock shortages

Student Ghada Alsarheed @Ghada Alsarheed explained: “There are several factors to consider, such as the financial impact and the cumulative growth target of at least SAR 800 million in revenues during the first 5 years.
From a marketing perspective, success depends on a rapid market-penetration strategy that takes advantage of the substantial existing demand for weight-loss drugs, thereby reducing customer acquisition costs.
This financial inflow also provides flexibility to reinvest in portfolio diversification and achieve sustainable profitability over the long term by entering the high-margin biopharmaceutical sector.
As for competition in the diabetes and obesity drug market, it is experiencing unprecedented global and local demand, alongside supply chain challenges.
This is where the major opportunity lies for Avalon Pharma: offering the advantage of “abundance and availability” by providing a reliable equivalent alternative that addresses stock shortages.
A value-based pricing strategy also enables the company to capture broader consumer segments, spanning both therapeutic uses (diabetes) and cosmetic uses (weight loss).
The final point is the option to transfer manufacturing technology and strengthen pharmaceutical security. The right to transfer technology represents a fundamental shift from being merely an exclusive marketer and distributor to achieving local industrial sovereignty.
This transition would free the company from global supply chain risks, increase confidence in the product, and align fully with Vision 2030 and support for government tenders under the “Made in Saudi Arabia” banner, paving the way for it to become a regional export hub.
The challenge of consumer trust and loyalty can be addressed through evidence-based medical marketing, including educational campaigns for doctors and patients and digital treatment-journey follow-up programs to ensure continuity.
Price competition can be addressed by focusing on value-based pricing, supported by continuous product availability and health insurance coverage, rather than engaging in a losing price war.
Likewise, reliance on external suppliers can be challenged by activating the local technology transfer provision as quickly as possible to make the most of national competitive advantages and export to Middle East and North Africa markets.”

Reducing import costs and building a market base that can compete regionally

Student Jumana Alshehri @Jumana Alshehri concluded the comprehensive analysis by saying: “I believe the agreement could be a turning point for Avalon Pharma, because the projected SAR 800 million in revenues gives the company an opportunity to expand its operations and improve its financial results.
With rising demand for diabetes and obesity drugs, the company can benefit from entering the market with a competitive product and build a larger market share.
Most importantly, transferring manufacturing to the Kingdom in the future will give it an additional advantage by reducing import costs, localizing pharmaceutical manufacturing, and supporting the objectives of Vision 2030.”

Financial and structural analysis of the agreement’s impact and future growth drivers

Avalon Pharma’s agreement to market tirzepatide comes at a time when the company is in a financial position to expand. Its revenues and profits grew 16% in the second quarter, led by the private sector, while its net margin remained stable at 21%. The agreement is significant in relative terms: its average target revenue is equivalent to about one-third of the company’s current sales, and it shifts its product mix toward higher-value prescription medicines.

The deeper value lies in the right to transfer manufacturing technology, which would eventually turn the company from a marketer of an imported product into its manufacturer, keeping the manufacturing margin within the Kingdom. This aligns with the Avalon 4 plant for sterile products and with a market where local production covers about one-third of pharmaceutical consumption, while demand for treatments for diabetes and metabolic diseases is growing.

The timing of returns depends on patent expirations, while success will depend on the company’s ability to compete on price when several generic versions enter the market simultaneously, and to finance sales that are collected after about six months. As the conversion of profits into cash continues to improve, the agreement is expected to shift from a deferred growth option to a key driver of the company’s profits over the long term.